Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MERTK | Q12866 | 2/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.37 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27252262 | 0.83 | MERTK (0.57) | MAPTMAPK1MERTKVCAM1LRRK2 | |
| SCHEMBL27252255 | 0.81 | MERTK (0.57) | MAPTMERTKVCAM1AHRFGFR4 | |
| SCHEMBL27252329 | 0.78 | TNF (0.40) | JAK2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL2543205 | 0.77 | CDK1 (0.46) | POLBMAPTMAPK1TDP1JAK2 | |
| SCHEMBL27261311 | 0.76 | TNF (0.41) | JAK2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL7187168 | 0.76 | EGFR (0.49) | TDP1JAK2JAK3LRRK2 | |
| SCHEMBL2543201 | 0.76 | LRRK2 (0.43) | POLBMAPTMAPK1MERTKVCAM1 | |
| SCHEMBL23927084 | 0.76 | MAPT (0.60) | POLBMAPTMAPK1PIN1FGFR4 | |
| SCHEMBL30079650 | 0.76 | MAPT (0.60) | POLBMAPTMAPK1PIN1FGFR4 | |
| SCHEMBL30989701 | 0.74 | VCAM1 (0.47) | POLBMAPTVCAM1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | POLB 2696/4885MAPT 3851/4885MAPK1 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.